Regeneron Pharmaceuticals REGN Equity Securities (Non-Current)

Equity Securities (Non-Current) at other companies

AmgenAMGN

——

IncyteINCY

——

Other financials

Income statement

See full

Revenue$3.6B+19.0%

Operating income$642.9M+8.6%

Net income$727.2M-10.1%

EPS (diluted)$6.75-7.1%

Balance sheet

See full

Cash & equivalents$3.0B-4.0%

Total debt$2.7B+0.1%

Total equity$31.4B+6.9%

Total assets$40.9B+8.9%

Cash flow

See full

Operating cash flow$1.1B+3.2%

CapEx$230.6M+0.6%

Free cash flow$848.3M+4.0%

Valuation

See full

Market cap$63.95B+17.8%

Enterprise value$63.68B+18.1%

P/E14.5×+2.4×

P/S4.3×+0.4×

Profitability

See full

Gross margin93.9%—

Operating margin24.3%-2.9pp

Net margin29.6%-2.3pp

Returns & leverage

See full

Return on equity14.5%-1.4pp

Debt / equity0.1×0.0×

Current ratio3.6×-1.4×

Where this comes from

Reported directly by Regeneron Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:EquitySecuritiesFVNINoncurrent.

The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Regeneron Pharmaceuticals's equity securities (non-current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Regeneron Pharmaceuticals's equity securities (non-current)?: Regeneron Pharmaceuticals (REGN) reported equity securities (non-current) of $48.7M in Q1 2026.